Akebia Expands Renal Disease Portfolio with Cyclerion’s Praliciguat
By Sasha Yachu & Michelle Liu
Pharma Deals Review: Vol 2021 Issue 6 (Table of Contents)
Published: 30 Jun-2021
DOI: 10.3833/pdr.v2021.i6.2619 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Aiming to expand its presence in the renal diseases segment, Akebia Therapeutics has agreed to acquire the global licensing rights to Cyclerion Therapeutics’ praliciguat, an oral soluble guanylate cyclase stimulator...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS